Associated Papers
Short-Term Responders of Non-Small Cell Lung Cancer Patients to EGFR Tyrosine Kinase Inhibitors Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms.
Xu Y et al.
Translational Oncology, 2018
Select a paper to view details